NCT06767540

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

A Randomized Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of AK120 in the Treatment of Moderate-to-severe Atopic Dermatitis (AD) in Adolescents

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 198 (estimated)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 12 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.

Detailed description

This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the safety and efficacy of AK120 in the treatment of moderate-to-severe AD in adolescents. The total duration of the study planned is approximately 57 weeks.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Placebo	placebo subcutaneous injection Q2W until week 46.
DRUG	placebo	placebo subcutaneous injection Q3W until week 45.

Timeline

• Start date: 2025-01-23
• Primary completion: 2027-07-10
• Completion: 2027-07-10
• First posted: 2025-01-10
• Last updated: 2025-01-10

Locations

28 sites across 1 country: China